Table 3. Percentage of patients experiencing the most common AEs (all grades; ⩾25% of all patients) and grade 3 or 4 AEs (⩾5% of all patients).

	Bortezomib/docetaxel doses (mg m−2 dose−1)
	1.0/60 n=3	1.0/75 n=3	1.0/100 n=11	1.3/75 n=11	1.3/100 n=4	1.5/75 n=16	Total n=48
AE (all grades)
Diarrhoea	100	67	73	82	100	75	79
Nausea	100	67	64	73	50	56	65
Alopecia	33	67	55	64	75	50	56
Asthenia	33	67	55	82	50	44	56
Vomiting	67	33	36	82	25	50	52
Neutropenia	100	67	45	55	25	38	48
Myalgia	67	100	45	45	50	31	46
Anorexia	33	33	27	73	75	31	44
Peripheral neuropathy	0	67	36	64	50	31	42
Dysgeusia	33	67	45	64	50	13	40
Paresthesia	0	67	36	64	50	25	40
Fatigue	67	33	36	27	50	31	35
Arthralgia	67	67	27	45	25	19	33
Conjunctivitis	0	67	55	18	50	13	29
Headache	67	33	36	27	25	19	29
Constipation	33	0	27	45	25	19	27
Pyrexia	0	33	27	27	25	31	27
Mucosal inflammation	0	33	36	27	25	19	25
Neuralgia	0	33	36	36	25	13	25
AE (grade 3/4)
Neutropenia	100	33	45	55	25	31	44
Febrile neutropenia	0	0	18	18	50	19	19
Diarrhoea	33	0	18	27	25	13	19
Peripheral neuropathy	0	0	9	9	0	19	10
Leukopenia	0	33	27	0	0	6	10
Asthenia	0	33	0	18	0	6	8
Fatigue	0	0	0	0	25	13	6
Neuralgia	0	0	0	0	25	13	6

AEs=adverse events.